Acticor Biotech announced on Tuesday that it intends to unveil clinical results from its Phase 2/3 study in stroke next month.

The biopharmaceutical company explains that it plans to present these data at the European Stroke Organization Conference (ESOC), to be held from May 15 to 17 in Basel.

Quoted in a press release, Sophie Binay, the company's Managing Director and Chief Scientific Officer, points out that this meeting should represent a "crucial milestone" for Acticor.

We are convinced that glenzocimab is a promising drug candidate to address the major global medical challenge of stroke", she added.

Results from the Phase 1b/2a study showed that glenzocimab reduced mortality and intracerebral hemorrhage in stroke patients.

The share price, which has climbed 31% since the start of the year, was still up 2% today.

Copyright (c) 2024 CercleFinance.com. All rights reserved.